Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer-Reference-Cited by-同舟云学术

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer

Published:2011-02 Issue:3 Volume:317 Page:262-275
ISSN:0014-4827
Container-title:Experimental Cell Research
language:en
Short-container-title:Experimental Cell Research

Author:

Chauchereau Anne,Al Nakouzi Nader,Gaudin Catherine,Le Moulec Sylvestre,Compagno Daniel,Auger Nathalie,Bénard Jean,Opolon Paule,Rozet François,Validire Pierre,Fromont Gaëlle,Fizazi Karim

Funder

Association pour la Recherche sur les Tumeurs de la Prostate

Association pour la Recherche sur le Cancer

ARTP

Prostate Cancer Research Fundation

SALES Fundation

Publisher

Elsevier BV

Subject

Cell Biology

Reference49 articles.

1. Prostate cancer update: 2007;Lin;Curr. Opin. Oncol.,2008

2. Preclinical models of prostate cancer;Fizazi;Bull. Cancer,2005

3. Cell lines used in prostate cancer research: a compendium of old and new lines-part 2;Sobel;J. Urol.,2005

4. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA;Koochekpour;Prostate,2004

5. Establishment and characterization of a human primary prostate carcinoma cell line, HH870;Selvan;Prostate,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Failure to progress: breast and prostate cancer cell lines in developing targeted therapies;Cancer and Metastasis Reviews;2024-07-26

2. A vitamin D‐based strategy overcomes chemoresistance in prostate cancer;British Journal of Pharmacology;2024-07-09

3. Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors;Clinical Cancer Research;2023-06-26

4. Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer;International Journal of Molecular Sciences;2023-02-04

5. Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer;Nature Communications;2022-08-13